Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Decreases By 23.9%

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 995,395 shares, a decline of 23.9% from the February 26th total of 1,307,493 shares. Currently, 3.2% of the company’s shares are short sold. Based on an average daily volume of 1,654,814 shares, the days-to-cover ratio is presently 0.6 days.

Liminatus Pharma Stock Down 3.9%

Liminatus Pharma stock opened at $0.19 on Friday. The company has a market capitalization of $5.82 million and a PE ratio of -1.56. Liminatus Pharma has a 12-month low of $0.18 and a 12-month high of $33.66. The firm’s fifty day moving average is $0.50 and its 200 day moving average is $0.92.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.